TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11166983

Group type: EXPERIMENTAL
Intervention: Pleasant pictures
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Unpleasant pictures with pain-related material
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Unpleasant pictures without pain-related material
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Neutral pictures
Number of subjects: 104
Study: 11270028

Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms kg‐1
Number of subjects: 35

Group type: COMPARATOR
Intervention: Hydroxyzine 1 mg kg‐1
Number of subjects: 35
Study: 9298432

Group type: EXPERIMENTAL
Intervention: Problem-focused training
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Emotion-focused training
Number of subjects: 29

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 29
Study: 8348281

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) doses ranging from 5 to 20 mg
Number of subjects: 0
Study: 3525169

Group type: EXPERIMENTAL
Intervention: Sones or Gensini catheters (group A)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Pigtail catheters (group B)
Number of subjects: 170
Study: 31420983

Group type: EXPERIMENTAL
Intervention: Optimized adaptive design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimized nonadaptive design
Number of subjects: 0
Study: 30021711

Group type: EXPERIMENTAL
Intervention: ISG + cCBT
Number of subjects: 302

Group type: COMPARATOR
Intervention: cCBT alone
Number of subjects: 302
Study: 27421881

Group type: EXPERIMENTAL
Intervention: Top-down intervention (general health education and mHealth intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (top-down intervention and peer education)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Top-down intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 26021111

Group type: EXPERIMENTAL
Intervention: Collagen PVP
Number of subjects: 0

Group type: COMPARATOR
Intervention: hylan GF-20
Number of subjects: 0
Study: 23162576

Group type: EXPERIMENTAL
Intervention: Aloe vera gel (A.V. 2% oral gel)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 21197497

Group type: EXPERIMENTAL
Intervention: Splinted cemented restorations
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonsplinted cemented restorations
Number of subjects: 44
Study: 18543329

Group type: EXPERIMENTAL
Intervention: Tetracycline (500 mg orally twice a day for 28 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 15910187

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) + Pulsed Dye Laser (PDL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pulsed Dye Laser (PDL) alone
Number of subjects: 24
Study: 12627310

Group type: EXPERIMENTAL
Intervention: High Intensity (HI) training group (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low Intensity (LO) training group (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both HI and LO training groups
Number of subjects: 20
Study: 10584468

Group type: EXPERIMENTAL
Intervention: Maternal nursing care (mothers' group)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Professional nursing care (nurses' group)
Number of subjects: 362
Study: 8917229

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 24
Study: 1872042

Group type: EXPERIMENTAL
Intervention: Felbinac Gel 3% (1 g, three times daily)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 281
Study: 29103065

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (2 weekly sessions for 12 months)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Reference group (health-promoting lectures)
Number of subjects: 116
Study: 25800784

Group type: EXPERIMENTAL
Intervention: TDF monotherapy (300 mg/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: TDF and ETV combination therapy (TDF 300 mg/day and ETV 1 mg/day)
Number of subjects: 102
Study: 24827808

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² on days 21, 28, 35, 42, 175, 182, 189, and 196)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No rituximab
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 84
Study: 22751980

Group type: EXPERIMENTAL
Intervention: Combined anticoagulant-aspirin therapy (100-mg prophylactic dose)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy
Number of subjects: 213

Group type: COMPARATOR
Intervention: Aspirin therapy (100-mg prophylactic dose)
Number of subjects: 213
Study: 20119899

Group type: EXPERIMENTAL
Intervention: Sprayed fibrin glue (study group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 10
Study: 18309485

Group type: EXPERIMENTAL
Intervention: S-1 treatment
Number of subjects: 33
Study: 17035614

Group type: EXPERIMENTAL
Intervention: 30 mEq of oral potassium citrate (Kcitrate)
Number of subjects: 161

Group type: COMPARATOR
Intervention: 30 mEq of potassium chloride (KCl)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Both K supplements
Number of subjects: 161
Study: 12784322

Group type: EXPERIMENTAL
Intervention: Sampling schedules with 5%, 10%, or 50% of period 2 C(max) value added to observed concentrations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjects with time 0 concentrations of 1%-10% of period 2 C(max) included or excluded in simulations.
Number of subjects: 0

Group type: COMPARATOR
Intervention: True data with no carryover between periods.
Number of subjects: 0
Study: 11085844

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer screening methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domestic violence interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sexual dysfunction treatments
Number of subjects: 0
Study: 8694302

Group type: EXPERIMENTAL
Intervention: 10% HES (mean molecular weight 200,000 daltons)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Human albumin 20% (HA)
Number of subjects: 60
Study: 1550062

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 47
Study: 4016827

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1,000 mg once daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cefaclor 250 mg TID
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 200
Study: 31469026

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate (IngMeb)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Diclofenac sodium (DS)
Number of subjects: 502
Study: 30886933

Group type: EXPERIMENTAL
Intervention: 16-week physical activity and nutrition program
Number of subjects: 576

Group type: COMPARATOR
Intervention: 4-session health and wellness workshop
Number of subjects: 576
Study: 28452086

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 117

Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Nifedipine and Atosiban
Number of subjects: 117
Study: 26310909

Group type: EXPERIMENTAL
Intervention: CT-guided CESI
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: CLO fluoroscopy-guided CESI
Number of subjects: 186

Group type: COMPARATOR
Intervention: APL fluoroscopy-guided CESI
Number of subjects: 186
Study: 24743675

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with double-sided polypropylene mesh (29 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication without mesh (31 patients)
Number of subjects: 60
Study: 22282429

Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both IPT and CBT
Number of subjects: 90
Study: 20167476

Group type: EXPERIMENTAL
Intervention: EGFR gene amplification assessment using fluorescent in situ hybridisation
Number of subjects: 315
Study: 18716314

Group type: EXPERIMENTAL
Intervention: Generic enoxaparin (40 mg, single-dose subcutaneous administration)
Number of subjects: 20
Study: 16273477

Group type: EXPERIMENTAL
Intervention: Asymptomatic ICA stenosis ≥70% (GI)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Symptomatic ICA stenosis (GII)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Asymptomatic ICA stenosis (GI)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both groups (GI and GII)
Number of subjects: 109
Study: 12234503

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1218
Study: 10550150

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² on days 1, 8, and 15 plus cisplatin 100 mg/m² on day 2, every 28 days
Number of subjects: 307

Group type: COMPARATOR
Intervention: Mitomycin 6 mg/m², ifosfamide 3,000 mg/m², and mesna on day 1 plus cisplatin 100 mg/m² on day 2, every 28 days
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin (GC)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Mitomycin, ifosfamide, and cisplatin (MIC)
Number of subjects: 307
Study: 7770260

Group type: EXPERIMENTAL
Intervention: 2 g/day of elemental calcium
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Calcium and Placebo
Number of subjects: 75
Study: 1703780

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 0
Study: 378732

Group type: EXPERIMENTAL
Intervention: Butorphanol (1 mg and 2 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Meperidine (40 mg and 80 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 200
Study: 31912371

Group type: EXPERIMENTAL
Intervention: Mechanical vibration device (AcceleDent Aura)
Number of subjects: 21
Study: 30556911

Group type: EXPERIMENTAL
Intervention: 2% tofacitinib ointment applied twice daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 28092795

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training (EX, n=210)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Non-exercise control (NON-EX, n=209)
Number of subjects: 419
Study: 26605849

Group type: EXPERIMENTAL
Intervention: Gene therapy with subretinal delivery of a recombinant adeno‐associated viral vector carrying RPE65
Number of subjects: 8
Study: 23218844

Group type: EXPERIMENTAL
Intervention: Adapted form of individual short‐term psychodynamic psychotherapy (ASTPP) - 25 sessions, 1 session/week
Number of subjects: 46

Group type: COMPARATOR
Intervention: Primary care management (TAU) - 4 consultations/6 months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ASTPP
Number of subjects: 46

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 46
Study: 21615309

Group type: EXPERIMENTAL
Intervention: scTox-Tr group (n = 19) - patients who adhered to the exercise intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: scTox-Sed group (n = 17) - patients who did not adhere to the exercise intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (C) - 48 subjects
Number of subjects: 36
Study: 19547808

Group type: EXPERIMENTAL
Intervention: Clozapine (n=115, 75-600 mg)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Haloperidol (n=105, dose range 2-15 mg)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Chlorpromazine (n=105, 100-400 mg)
Number of subjects: 325
Study: 16679276

Group type: EXPERIMENTAL
Intervention: FAIR (Flow‐sensitive Alternating Inversion Recovery) magnetic resonance imaging technique
Number of subjects: 26
Study: 14560228

Group type: EXPERIMENTAL
Intervention: Fibrin sealant Beriplast P (FSBP)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Thrombin-soaked gelatin sponge (TSG)
Number of subjects: 201
Study: 10352065

Group type: EXPERIMENTAL
Intervention: Witness Project (culturally competent cancer education program)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 410
Study: 8879890

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg PO QD, titrated to 50 mg losartan/12.5 mg HCTZ PO QD after 4 weeks, then to 50 mg losartan/25 mg HCTZ PO QD after 8 weeks)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Amlodipine (5 mg PO QD, titrated to 10 mg PO QD after 4 weeks, then to 10 mg plus 25 mg HCTZ PO QD after 8 weeks)
Number of subjects: 190
Study: 1999863

Group type: EXPERIMENTAL
Intervention: Skewflap
Number of subjects: 191

Group type: COMPARATOR
Intervention: Long posterior flap
Number of subjects: 191
Study: 6465669

Group type: EXPERIMENTAL
Intervention: Inhaled vasoactive intestinal peptide (VIP) 100 micrograms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control solution (1% human serum albumin in 2 ml 0.9% saline)
Number of subjects: 6
Study: 30779971

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) with bioDensity™
Number of subjects: 300
Study: 29433457

Group type: EXPERIMENTAL
Intervention: Formula containing a mix of dairy fat and plant oils (D)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Formula containing plant oils (P)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Formula containing plant oils supplemented with ARA and DHA (PDHA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Breastfed infants (BF)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 70
Study: 26875905

Group type: EXPERIMENTAL
Intervention: Shock wave therapy (SW group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (drug therapy)
Number of subjects: 52
Study: 24824095

Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nonoperative treatment (nonweight bearing and early range of motion exercise)
Number of subjects: 56
Study: 23190521

Group type: EXPERIMENTAL
Intervention: High flux dialyzers
Number of subjects: 312

Group type: COMPARATOR
Intervention: Low flux dialyzers
Number of subjects: 312
Study: 20716300

Group type: EXPERIMENTAL
Intervention: Treatment addressing anxiety symptoms
Number of subjects: 526
Study: 17055165

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 23
Study: 16294506

Group type: EXPERIMENTAL
Intervention: New nevirapine tablet formulation (test, T)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference nevirapine tablet formulation (R)
Number of subjects: 24
Study: 11923816

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (bemiparin sodium 3500 IU/daily subcutaneously)
Number of subjects: 100
Study: 9917487

Group type: EXPERIMENTAL
Intervention: Formula A (Similac With Iron Powder)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Formula B (Enfamil With Iron Powder)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Transition from breast milk to formula A
Number of subjects: 169
Study: 7577777

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine followed by a continuous infusion of 7 mL/h 0.25% bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 2122869

Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg/day after impregnation)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo phase (2 weeks) followed by 6 weeks of active treatment
Number of subjects: 43
Study: 354922

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 45
Study: 31791239

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 1 μg·kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline at 0.01 ml·kg‐1
Number of subjects: 40
Study: 28932090

Group type: EXPERIMENTAL
Intervention: High dose (400 mg) HL tablet
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Low dose (133.4 mg) HL tablet
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 26116614

Group type: EXPERIMENTAL
Intervention: Combined functional anaerobic and strength training (12-week programme, 3 sessions per week, 75 minutes each session)
Number of subjects: 40
Study: 24120711

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 21471845

Group type: EXPERIMENTAL
Intervention: Artcereb (artificial cerebrospinal fluid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 20
Study: 19217598

Group type: EXPERIMENTAL
Intervention: 18F vacuum drain plus COSEAL
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 18F vacuum drain plus BioGlue
Number of subjects: 77

Group type: COMPARATOR
Intervention: 18F vacuum drain
Number of subjects: 77
Study: 17596727

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 32
Study: 15285274

Group type: COMPARATOR
Intervention: Gingko biloba (GB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination of Codonopsis pilosula (CPG) and Gingko biloba (GB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11583941

Group type: EXPERIMENTAL
Intervention: Sirolimus at 2 mg/d
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Sirolimus at 5 mg/d
Number of subjects: 719

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Sirolimus (both doses)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: All groups (Sirolimus and Azathioprine)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 719
Study: 9250437

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 14
Study: 7936292

Group type: EXPERIMENTAL
Intervention: Graded levels of dysphagia therapist control of diet consistency and reinforcement of compensatory swallowing techniques
Number of subjects: 115

Group type: COMPARATOR
Intervention: Limited patient and family instruction regarding diet modification and compensatory swallowing techniques
Number of subjects: 115
Study: 2643672

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine chewing gum
Number of subjects: 223

Group type: COMPARATOR
Intervention: Basic intervention alone (no gum)
Number of subjects: 223
Study: 786045

Group type: EXPERIMENTAL
Intervention: THC (20 mg) in fast condition
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: THC (20 mg) in slow condition
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Alcohol (intoxicating doses)
Number of subjects: 6
Study: 30717700

Group type: EXPERIMENTAL
Intervention: Training workshops (two four-hour sessions) and homework assignments on advance care planning and shared decision-making.
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Training workshops and supporting materials for staff.
Number of subjects: 311
Study: 28479221

Group type: EXPERIMENTAL
Intervention: Behavioral interventions based on the Common-Sense Model of Self-Regulation (CSM) to change parental illness perception.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caregivers who believed baby teeth do matter.
Number of subjects: 0
Study: 25746966

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Inhaled ipratropium bromide
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (budesonide)
Number of subjects: 1264
Study: 24519693

Group type: EXPERIMENTAL
Intervention: Tandospirone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0
Study: 21627766

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 1,200 mg (624 mg-equivalents gabapentin), twice daily for 14 days
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo, twice daily for 14 days
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Gabapentin capsules
Number of subjects: 101
Study: 19656101

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 123
Study: 22157410

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Non-CABG (percutaneous coronary intervention plus medical treatment)
Number of subjects: 611
Study: 16507375

Group type: EXPERIMENTAL
Intervention: CSDVC (clindamycin phosphate 2% single-dose vaginal cream)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CVC (7-day regimen of clindamycin phosphate 2% vaginal cream)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSDVC
Number of subjects: 0

Group type: COMPARATOR
Intervention: CVC
Number of subjects: 0
Study: 12869610

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg tablet)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11